Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 0.68 | 0.10 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 3.79 | 0.90 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 19 | 27 | 11 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.88 | 0.75 | 1.22 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 13 | 13 | 17 | 20 | 13 | ||||
| Gross margin, % | — | — | — | — | — | 21.81 | 21.81 | 21.32 | 11.89 | 10.32 | |||||
| EBT | — | — | — | — | — | 1 | (2) | 2 | 0 | (1) | |||||
| EBT margin, % | — | — | — | — | — | 8.13 | 0.00 | 9.14 | 0.18 | (8.40) | |||||
| Net income | — | — | — | — | — | 0 | 0 | 1 | 0 | (1) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 1.83 | 2.27 | 1.99 | 0.82 | ||||
| Earnings | — | — | — | — | — | — | 0.15 | 0.18 | 0.00 | (0.07) | |||||
| Cash flow | — | — | — | — | — | — | 0.25 | (0.05) | 0.06 | (0.05) | |||||
| Capex | — | — | — | — | — | — | (0.02) | (0.01) | (0.02) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | 0.24 | (0.06) | 0.04 | (0.05) | |||||
| Book value | — | — | — | — | — | 0.00 | 0.09 | 0.58 | 0.49 | 0.59 | |||||
| Shares, m | — | — | — | — | — | — | 7 | 7 | 10 | 16 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.47) | 5.00 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 2 | 0 | 1 | (1) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | 2 | 0 | 0 | (1) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 5 | 5 | 6 | 9 | ||||
| Total debt | — | — | — | — | — | 0 | 0 | 1 | 2 | 1 | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 1 | (1) | 1 | |||||
| Shareholders’ equity | — | — | — | — | — | 1 | 1 | 4 | 5 | 10 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 31.71 | 19.49 | (0.30) | (10.21) | ||||
| ROIC | — | — | — | — | — | 395.14 | 0.00 | 19.79 | 2.11 | (6.07) | |||||
| ROE | — | — | — | — | — | 0.00 | 0.00 | 54.96 | (0.59) | (15.59) | |||||
Negative figures in brackets.
Fiscal years to Mar 2026
Charts ten years each
Cellyan Biotechnology Co., Ltd vs peers in Medical Distribution (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CAH Cardinal Health, Inc. | $58.8B | 35.0× | 23.3× | +5.84% (above 0%: growing) | +68.32% (above 0%: growing) | +10.87% (above 0%: growing) | 4.02% | 1.14% | Compare |
| HSIC Henry Schein, Inc. | $9.7B | 25.0× | 18.5× | +6.73% (above 0%: growing) | +16.90% (above 0%: growing) | +140.91% (above 0%: growing) | 31.84% | 4.95% | Compare |
| AHG Akso Health Group Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +263.89% (above 0%: growing) | n/m | −12,975.04% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FOCL FocalTherics | $154.8M | — (loss-making) | — (loss-making) | +38.85% (above 0%: growing) | n/m | +21.49% (above 0%: growing) | 55.59% | (60.83%) | Compare |
| COSM Cosmos Health Inc. | $33.9M | — (loss-making) | 25.1× | +28.76% (above 0%: growing) | n/m | +9.39% (above 0%: growing) | 7.96% | (15.41%) | Compare |
| ACH Accendra Health, Inc. | $20.1M | — (loss-making) | — (loss-making) | −10.07% (below 0%: shrinking) | n/m | −1,624.82% (below 0%: shrinking) | 42.95% | (5.73%) | Compare |
| HKPD Cellyan Biotechnology Co., Ltd | $17.1M | — | — | — | — | −90.45% (below 0%: shrinking) | — | — | |
| YI 111, Inc. Sponsored ADR | $16.0M | — (loss-making) | — (loss-making) | −29.61% (below 0%: shrinking) | n/m | −185.70% (below 0%: shrinking) | 5.33% | (0.85%) | Compare |
| SNYRQ Synergy CHC Corp. | $1.3M | — (loss-making) | 1.6× | −32.77% (below 0%: shrinking) | n/m | −148.51% (below 0%: shrinking) | 72.29% | (10.32%) | Compare |
| Median of peers | $94.3M | — | 20.9× | +6.29% | — | −69.56% | 19.90% | (3.29%) |
Cellyan Biotechnology Co., Ltd (HKPD) key facts
- Concern: Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
- Cellyan Biotechnology Co., Ltd (HKPD) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HKPD traded at $0.11, a market capitalization of $17.1 million.
- Return on equity was −15.6% and debt-to-equity 0.10.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 3.39 (safe zone) for fiscal 2026.